<< Вернуться к списку статей журнала

Том 23 №2 - Приложение 2021 год - Нефрология и диализ

Клинические практические рекомендации KDIGO 2020 по тактике ведения диабета при хронической болезни почек

Перевод на русский язык А.Ю. Денисова под редакцией Е.В. Захаровой

DOI: 10.28996/2618-9801-2021-2suppl-9-121

Аннотация: Клинические практические рекомендации Инициативы по улучшению глобальных исходов заболеваний почек/Kidney Disease: Improving Global Outcomes (KDIGO) по тактике ведения диабета при хронической болезни почек (ХБП) 2020 года представляют собой первое руководство KDIGO по данному вопросу. Сфера охвата включает такие темы, как всесторонняя помощь, мониторинг гликемии и целевые показатели, образ жизни и антигипергликемические препараты, а также подходы к самоконтролю и оптимальные модели лечения. Цель рекомендаций состоит в том, чтобы создать полезный ресурс для врачей и пациентов путем предоставления действенных рекомендаций с инфографикой, основанных на строгом формальном систематическом обзоре литературы. Другая цель состоит в том, чтобы предложить рекомендации по проведению исследований в областях, в которых имеются пробелы в знаниях. Руководство предназначено для широкой аудитории врачей, занимающихся лечением диабета и ХБП, принимая при этом в расчет значение для политики здравоохранения и затраты. Разработка данного руководства проводилась в рамках открытого процесса обзора и оценки доказательств. Подходы к лечению и рекомендации основаны на систематических обзорах соответствующих исследований, оценке качества доказательств и обоснованности рекомендаций в соответствии с системой классификации, оценки, разработки и экспертизы рекомендаций (шкала GRADE). В данных рекомендациях обсуждаются ограничения доказательств, а также представлены области для будущих исследований.

Для цитирования: Перевод на русский язык А.Ю. Денисова под редакцией Е.В. Захаровой Клинические практические рекомендации KDIGO 2020 по тактике ведения диабета при хронической болезни почек. Нефрология и диализ. 2021. 23(2):9-121. doi: 10.28996/2618-9801-2021-2suppl-9-121

Весь текст

Ключевые слова: агонист рецептора ГПП-1, блокатор рецептора ангиотензина II, гемодиализ, гликемия, диализ, ингибитор ангиотензинпревращающего фермента, ингибиторы НГЛТ2, командный подход к оказанию помощи, метформин, модели оказания помощи, мониторинг гликемии, научно обоснованный образ жизни, питание, ренин-ангиотензиновая система, руководство, самоконтроль, систематический обзор, хроническая болезнь почек, целевые показатели гликемии, HbA1c, KDIGO, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, chronic kidney disease, dialysis, evidence-based, GLP-1 receptor agonist, glycemia, glycemic monitoring, glycemic targets, guideline, HbA1c, hemodialysis, KDIGO, lifestyle, metformin, models of care, nutrition, renin-angiotensin system, self-management, SGLT2 inhibitor, systematic review, team-based care

Список литературы:

1. Arnett DK, Khera A, Blumenthal RS. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: part 1, lifestyle and behavioral factors. JAMA Cardiol. 2019;4:1043-1044.
2. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082-1115.
3. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010; 56:956-965.
4. Perkovic V, Agarwal R, Fioretto P, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90:1175-1183.
5. Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633-644.
6. Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298-2307.
7. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
8. Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov. 2016;15:568-588.
9. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
10. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577-1578.
11. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
12. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499-1507.
13. Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;6:CD006257.
14. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
15. Ahmad J, Shafique S, Abidi SM, et al. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract. 2003; 60:131-138.
16. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20:1576-1581.
17. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992;41:912-919.
18. Bakris GL, Slataper R, Vicknair N, et al. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications. 1994;8:2-6.
19. Bojestig M, Karlberg BE, Lindstrom T, et al. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care. 2001;24:919-924.
20. Capek M, Schnack C, Ludvik B, et al. Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study. Clin Investig. 1994;72:961-966.
21. Chase HP, Garg SK, Harris S, et al. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol. 1993;25:284-289.
22. Cordonnier DJ, Pinel N, Barro C, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol. 1999;10: 1253-1263.
23. Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care. 1998;21:104-110.
24. Garg S, Chase HP, Jackson WE, et al. Renal and retinal changes after treatment with Ramipril and pentoxifylline in subjects with IDDM. Ann Ophthalmology-Glaucoma. 1998;30:33-37.
25. Hansen KW, Klein F, Christensen PD, et al. Effects of captopril on ambulatory blood pressure, renal and cardiac function in microalbuminuric type 1 diabetic patients. Diabete Metab. 1994;20:485-493.
26. Hommel E, Jensen B, Parving H. Long-term effect of captopril on kidney function in normotensive insulin dependent diabetic patients (iddm) with diabetic nephropathy [abstract]. J Am Soc Nephrol. 1995;6:450.
27. Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37:890-899.
28. Katayama S, Kikkawa R, Isogai S, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract. 2002;55:113-121.
29. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99:497-504.
30. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
32. Marre M, Leblanc H, Suarez L, et al. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J (Clin Res Ed). 1987;294:1448-1452.
33. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945.
34. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81-87.
35. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.
36. Muirhead N, Feagana BF, Mahona J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res. 1999;60:650-660.
37. Nankervis A, Nicholls K, Kilmartin G, et al. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism. 1998;47:12-15.
38. O’Hare P, Bilbous R, Mitchell T, et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care. 2000;23:1823-1829.
39. Phillips PJ, Phillipou G, Bowen KM, et al. Diabetic microalbuminuria and cilazapril. Am J Med. 1993;94:58S-60S.
40. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577-581.
41. Romero R, Salinas I, Lucas A, et al. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. Diabetes Care. 1993;16:597-600.
42. Sano T, Kawamura T, Matsumae H, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994;17: 420-424.
43. Tong PC, Ko GT, Chan WB, et al. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency. Diabetes Obes Metab. 2006;8:342-347.
44. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978-2986.
45. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641-2650.
46. Perrin NE, Jaremko GA, Berg UB. The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial. Pediatr Nephrol. 2008;23:947-954.
47. Tan KC, Chow WS, Ai VH, et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev. 2002;18:71-76.
48. Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013;62:3224-3231.
49. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012;110:383-391.
50. Coresh J, Heerspink HJL, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7:115-127.
51. Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128-139.
52. Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996;15:72-78.
53. World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Available at: https://apps.who.int/iris/handle/10665/259481. Accessed August 14, 2020.
54. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907-917.
55. Persson F, Lindhardt M, Rossing P, et al. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review. J Renin Angiotensin Aldosterone Syst. 2016;17:1470320316652047.
56. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med. 2000;160:685-693.
57. Remuzzi G, Ruggenenti P, Perna A, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol. 2004;15:3117-3125.
58. Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017;356:j791.
59. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60:444-450.
60. Hanssens M, Keirse MJ, Vankelecom F, et al. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol. 1991;78:128-135.
61. Shotan A, Widerhorn J, Hurst A, et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med. 1994;96:451-456.
62. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443-2451.
63. Bateman BT, Patorno E, Desai RJ, et al. Angiotensin-converting enzyme inhibitors and the risk of congenital malformations. Obstet Gynecol. 2017;129:174-184.
64. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158:26-32.
65. Ahuja TS, Freeman D Jr, Mahnken JD, et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol. 2000;20:268-272.
66. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585-592.
67. Linde C, Bakhai A, Furuland H, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc. 2019;8:e012655.
68. Singhania G, Ejaz AA, McCullough PA, et al. Continuation of chronic heart failure therapies during heart failure hospitalization - a review. Rev Cardiovasc Med. 2019;20:111-120.
69. Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97:42-61.
70. Ray K, Dorman S, Watson R. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. J Hum Hypertens. 1999; 13:717-720.
71. Mukete BN, Rosendorff C. Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium-a meta-analysis. J Am Soc Hypertens. 2013;7:454-466.
72. Nilsson E, Gasparini A, Arnlov J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277-284.
73. Roush GC, Ernst ME, Kostis JB, et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65:1041-1046.
74. Roush GC, Sica DA. Diuretics for hypertension: a review and update. Am J Hypertens. 2016;29:1130-1137.
75. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158:741-751.
76. Tannen RL. Diuretic-induced hypokalemia. Kidney Int. 1985;28:988-1000.
77. Wilmer WA, Rovin BH, Hebert CJ, et al. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol. 2003;14:3217-3232.
78. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314:151-161.
79. Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14:798-809.
80. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-1903.
81. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-2213.
82. Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094-2102.
83. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-2068.
84. Bolignano D, Palmer SC, Navaneethan SD, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004.
85. Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017;26:50-55.
86. Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50:333-344.
87. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540-1550.
88. Trevisan M, de Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20:1217-1226.
89. Xia J, Wang L, Ma Z, et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant. 2017; 32:475-487.
90. Jhee JH, Joo YS, Kee YK, et al. Secondhand smoke and CKD. Clin J Am Soc Nephrol. 2019;14:515-522.
91. Staplin N, Haynes R, Herrington WG, et al. Smoking and adverse outcomes in patients with CKD: The Study of Heart and Renal Protection (SHARP). Am J Kidney Dis. 2016;68:371-380.
92. Dinakar C, O’Connor GT. The health effects of electronic cigarettes. N Engl J Med. 2016;375:1372-1381.
93. Sawicki PT, Muhlhauser I, Bender R, et al. Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. J Intern Med. 1996;239:345-352.
94. Pan A, Wang Y, Talaei M, et al. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation. 2015;132:1795-1804.
95. Formanek P, Salisbury-Afshar E, Afshar M. Helping patients with ESRD and earlier stages of CKD to quit smoking. Am J Kidney Dis. 2018;72: 255-266.
96. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016;4:116-128.
97. Nakamura K, Nakagawa H, Murakami Y, et al. Smoking increases the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease. Kidney Int. 2015;88:1144-1152.
98. Stead LF, Koilpillai P, Fanshawe TR, et al. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016;3:CD008286.
99. de Boer IH, DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:24-30.
100. DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol. 2014;2:793-800.
101. DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366-2376.
102. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431-437.
103. Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55:636-643.
104. NGSP. Available at: http://ngsp.org/critsumm.asp. Accessed August 14, 2020.
105. College of American Pathologists. Hemoglobin A1c (5 Challenge) GH5-C 2019. Northfield, IL: College of American Pathologists;2019.
106. Freedman BI, Shihabi ZK, Andries L, et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol. 2010;31:375-379.
107. Jung M, Warren B, Grams M, et al. Performance of non-traditional hyperglycemia biomarkers by chronic kidney disease status in older adults with diabetes: results from the Atherosclerosis Risk in Communities Study. J Diabetes. 2018;10:276-285.
108. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631-1640.
109. Neelofar K, Ahmad J. A comparative analysis of fructosamine with other risk factors for kidney dysfunction in diabetic patients with or without chronic kidney disease. Diabetes Metab Syndr. 2019;13:240-244.
110. Williams ME, Mittman N, Ma L, et al. The Glycemic Indices in Dialysis Evaluation (GIDE) study: comparative measures of glycemic control in diabetic dialysis patients. Hemodial Int. 2015;19:562-571.
111. Chen HS, Wu TE, Lin HD, et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis. 2010;55:867-874.
112. Divani M, Georgianos PI, Didangelos T, et al. Comparison of glycemic markers in chronic hemodialysis using continuous glucose monitoring. Am J Nephrol. 2018;47:21-29.
113. Freedman BI, Shenoy RN, Planer JA, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int. 2010;30:72-79.
114. Fukami K, Shibata R, Nakayama H, et al. Serum albumin-adjusted glycated albumin reflects glycemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysis. J Diabetes Complications. 2015;29:913-917.
115. Harada K, Sumida K, Yamaguchi Y, et al. Relationship between the accuracy of glycemic markers and the chronic kidney disease stage in patients with type 2 diabetes mellitus. Clin Nephrol. 2014;82:107-114.
116. Hasslacher C, Kulozik F. Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I-III: a comparative study with HbA1c and glycated albumin. J Diabetes. 2016;8:712-719.
117. Hayashi A, Takano K, Masaki T, et al. Distinct biomarker roles for HbA1c and glycated albumin in patients with type 2 diabetes on hemodialysis. J Diabetes Complications. 2016;30:1494-1499.
118. Okada T, Nakao T, Matsumoto H, et al. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. Intern Med. 2011;50:23-29.
119. Raghav A, Ahmad J, Noor S, et al. Glycated albumin and the risk of chronic kidney disease in subjects with Type 2 diabetes: A study in North Indian population. Diabetes Metab Syndr. 2018;12:381-385.
120. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
121. Cho SJ, Roman G, Yeboah F, et al. The road to advanced glycation end products: a mechanistic perspective. Curr Med Chem. 2007;14:1653-1671.
122. Little RR, Rohlfing CL, Tennill AL, et al. Measurement of Hba(1C) in patients with chronic renal failure. Clin Chim Acta. 2013;418:73-76.
123. Tarim O, Kucukerdogan A, Gunay U, et al. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. PediatrInt. 1999;41:357-362.
124. American Diabetes Association. 6. glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S61-S70.
125. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73:1062-1068.
126. Zelnick LR, Batacchi ZO, Dinghe A, et al. Continuous glucose monitoring and use of alternative markers to assess clycemia in chronic kidney disease. Diabetes Care. https://doi.org/10.2337/dc20-0915. Accessed September 2, 2020.
127. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593-1603.
128. Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41:2275-2280.
129. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49:S12-S154.
130. Steno Study Group. Effect of 6 months of strict metabolic control on eye and kidney function in insulin-dependent diabetics with background retinopathy. Steno study group. Lancet. 1982;1:121-124.
131. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47:1703-1720.
132. Ciavarella A, Vannini P, Flammini M, et al. Effect of long-term near-normoglycemia on the progression of diabetic nephropathy. Diabete Metab. 1985;11:3-8.
133. Dahl-Jorgensen K. Near-normoglycemia and late diabetic complications. The Oslo Study. Acta Endocrinol Suppl (Copenh). 1987;284:1-38.
134. de Boer IH, Gao X, Cleary PA, et al. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study. Clin J Am Soc Nephrol. 2016;11:1969-1977.
135. DCCT/EDIC Research Group, Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
136. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet. 1986;2:1300-1304.
137. Reichard P, Britz A, Cars I, et al. The Stockholm Diabetes Intervention Study (SDIS): 18 months’ results. Acta Med Scand. 1988;224:115-122.
138. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865.
139. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and riskof complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
140. Abraira C, Emanuele N, Colwell J, et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care. 1992;15:1560-1571.
141. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
142. Crasto W, Morrison AE, Gray LJ, et al. The microalbuminuria education medication and optimisation (MEMO) study: 4 years follow-up of multifactorial intervention in high-risk individuals with type 2 diabetes. Diabet Med. 2019;37:286-297.
143. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360: 129-139.
144. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353:617-622.
145. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
146. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481-489.
147. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
148. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
149. Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017;6:CD010137.
150. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995;18:1113-1123.
151. Crasto W, Jarvis J, Khunti K, et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the microalbuminuria education and medication optimisation (MEMO) study. Diabetes Res Clin Pract. 2011;93:328-336.
152. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.
153. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
154. Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications. 2003; 17:314-322.
155. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371-378.
156. Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317:379-387.
157. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400-405.
158. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381:1707-1717.
159. Bach KE, Kelly JT, Palmer SC, et al. Healthy dietary patterns and incidence of CKD: a meta-analysis of cohort studies. Clin J Am Soc Nephrol. 2019;14:1441-1449.
160. Klahr S, Buerkert J, Purkerson ML. Role of dietary factors in the progression of chronic renal disease. Kidney Int. 1983;24:579-587.
161. Joint FAO/WHO/UNU Expert Consultation. Protein and amino acid requirements in human nutrition. World Health Organization: World Health Organization Technical Report Series, 2007.
162. Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst Rev. 2018; 10:CD001892.
163. Brouhard BH, LaGrone L. Effect of dietary protein restriction on functional renal reserve in diabetic nephropathy. Am J Med. 1990;89:427-431.
164. Ciavarella A, Di Mizio G, Stefoni S, et al. Reduced albuminuria after dietary protein restriction in insulin-dependent diabetic patients with clinical nephropathy. Diabetes Care. 1987;10:407-413.
165. Dullaart RP, Beusekamp BJ, Meijer S, et al. Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care. 1993;16: 483-492.
166. Dussol B, Iovanna C, Raccah D, et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. J Ren Nutr. 2005;15:398-406.
167. Hansen HP, Tauber-Lassen E, Jensen BR, et al. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62:220-228.
168. Jesudason DR, Pedersen E, Clifton PM. Weight-loss diets in people with type 2 diabetes and renal disease: a randomized controlled trial of the effect of different dietary protein amounts. Am J Clin Nutr. 2013;98:494-501.
169. Koya D, Haneda M, Inomata S, et al. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. Diabetologia. 2009;52:2037-2045.
170. Meloni C, Morosetti M, Suraci C, et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr. 2002; 12:96-101.
171. Raal FJ, Kalk WJ, Lawson M, et al. Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr. 1994;60:579-585.
172. Velazquez Lopez L, Sil Acosta MJ, Goycochea Robles MV, et al. Effect of protein restriction diet on renal function and metabolic control in patients with type 2 diabetes: a randomized clinical trial. Nutr Hosp. 2008;23:141-147.
173. Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:78-84.
174. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42:731-754.
175. Hostetter TH, Meyer TW, Rennke HG, et al. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int. 1986;30:509-517.
176. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2019;10226:795-808.
177. Chen X, Wei G, Jalili T, et al. The associations of plant protein intake with all-cause mortality in CKD. Am J Kidney Dis. 2016;67:423-430.
178. Haring B, Selvin E, Liang M, et al. Dietary protein sources and risk for incident chronic kidney disease: results from the atherosclerosis risk in communities (ARIC) study. J Ren Nutr. 2017;27:233-242.
179. Lew QJ, Jafar TH, Koh HW, et al. Red meat intake and risk of ESRD. J Am Soc Nephrol. 2017;28:304-312.
180. Ikizler TA, Burrowes JD, Byham-Gray LD, et al., KDOQI Nutrition in CKD Guideline Work Group. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis. 2020;76(suppl 1):S1-S107.
181. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-150.
182. Bergstrom J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol. 1995;6:1329-1341.
183. Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int. 1981;19:593-602.
184. Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371:624-634.
185. Juraschek SP, Miller ER 3rd, Weaver CM, et al. Effects of sodium reduction and the DASH diet in relation to baseline blood pressure. J Am Coll Cardiol. 2017;70:2841-2848.
186. Academies of Sciences, Engineering, and Medicine;Health and Medicine Division; Food and Nutrition Board; Committee to Review the Dietary Reference Intakes for Sodium and Potassium; Oria M, Harrison M, Stallings VA, eds. Dietary Reference Intakes for Sodium and Potassium. Available at: https://doi.org/10.17226/25353. Published March 5, 2019. Accessed August 14, 2020.
187. De’Oliveira JM, Price DA, Fisher ND, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int. 1997;52:771-777.
188. Dodson PM, Beevers M, Hallworth R, et al. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ. 1989;298:227-230.
189. Ekinci EI, Thomas G, Thomas D, et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care. 2009;32:1398-1403.
190. Houlihan CA, Allen TJ, Baxter AL, et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care. 2002;25:663-671.
191. Imanishi M, Yoshioka K, Okumura M, et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care. 2001;24:111-116.
192. Kwakernaak AJ, Krikken JA, Binnenmars SH, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2:385-395.
193. Lopes de Faria JB, Friedman R, de Cosmo S, et al. Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake. Nephron. 1997;76:411-417.
194. Miller JA. Sympathetic vasoconstrictive responses to high-and low-sodium diets in diabetic and normal subjects. Am J Physiol. 1995;269: R380-R388.
195. Miller JA. Renal responses to sodium restriction in patients with early diabetes mellitus. J Am Soc Nephrol. 1997;8:749-755.
196. Muhlhauser I, Prange K, Sawicki PT, et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia. 1996;39:212-219.
197. Petrie JR, Morris AD, Minamisawa K, et al. Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:1552-1557.
198. Suckling RJ, He FJ, Macgregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010:CD006763.
199. Trevisan R, Bruttomesso D, Vedovato M, et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes. 1998;47:1347-1353.
200. Vedovato M, Lepore G, Coracina A, et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia. 2004;47:300-303.
201. Yoshioka K, Imanishi M, Konishi Y, et al. Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care. 1998;21:482-486.
202. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;393:1958-1972.
203. Malta D, Petersen KS, Johnson C, et al. High sodium intake increases blood pressure and risk of kidney disease. From the Science of Salt: A regularly updated systematic review of salt and health outcomes (August 2016 to March 2017). J Clin Hypertens (Greenwich). 2018;20: 1654-1665.
204. World Health Organization. Guideline: Sodium Intake for Adults and Children, 2012. Available at: https://apps.who.int/iris/bitstream/handle/10665/77985/9789241504836_eng.pdf?sequence=1. Accessed August 14, 2020.
205. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Clin Diabetes. 2016;34:70-80.
206. Thomas MC, Moran J, Forsblom C, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861-866.
207. Zelle DM, Klaassen G, van Adrichem E, et al. Physical inactivity: a risk factor and target for intervention in renal care. Nat Rev Nephrol. 2017;13:152-168.
208. Navaneethan SD, Kirwan JP, Arrigain S, et al. Overweight, obesity and intentional weight loss in chronic kidney disease: NHANES 1999-2006. Int J Obes (Lond). 2012;36:1585-1590.
209. Beddhu S, Wei G, Marcus RL, et al. Light-intensity physical activities and mortality in the United States general population and CKD subpopulation. Clin J Am Soc Nephrol. 2015;10:1145-1153.
210. Pandey A, Garg S, Khunger M, et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation. 2015;132:1786-1794.
211. Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011;124:789-795.
212. Fletcher GF, Landolfo C, Niebauer J, et al. Reprint of: promoting physical activity and exercise: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:3053-3070.
213. Tran J, Ayers E, Verghese J, et al. Gait abnormalities and the risk of falls in CKD. Clin J Am Soc Nephrol. 2019;14:983-993.
214. Fried LF, Lee JS, Shlipak M, et al. Chronic kidney disease and functional limitation in older people: health, aging and body composition study. J Am Geriatr Soc. 2006;54:750-756.
215. Roshanravan B, Robinson-Cohen C, Patel KV, et al. Association between physical performance and all-cause mortality in CKD. J Am Soc Nephrol. 2013;24:822-830.
216. Johansen KL, Painter P. Exercise in individuals with CKD. Am J Kidney Dis. 2012;59:126-134.
217. Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2011;CD003236.
218. Leehey DJ, Moinuddin I, Bast JP, et al. Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study. Cardiovasc Diabetol. 2009;8:62.
219. Ekelund U, Steene-Johannessen J, Brown WJ, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women. Lancet. 2016;388:1302-1310.
220. Guthold R, Stevens GA, Riley LM, et al. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. Lancet Glob Health. 2018;6:e1077-e1086.
221. Biswas A, Oh PI, Faulkner GE, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med. 2015;162:123-132.
222. Agarwal R, Light RP. Physical activity and hemodynamic reactivity in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1660-1668.
223. Bowlby W, Zelnick LR, Henry C, et al. Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. BMC Nephrol. 2016;17:187.
224. Kosmadakis GC, John SG, Clapp EL, et al. Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease. Nephrol Dial Transplant. 2012;27:997-1004.
225. Robinson ES, Fisher ND, Forman JP, Curhan GC. Physical activity and albuminuria. Am J Epidemiol. 2010;171:515-521.
226. Beddhu S, Baird BC, Zitterkoph J, et al. Physical activity and mortality in chronic kidney disease (NHANES III). Clin J Am Soc Nephrol. 2009;4:1901-1906.
227. Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2:801-809.
228. Manfredini F, Mallamaci F, D’Arrigo G, et al. Exercise in patients on dialysis: a multicenter, randomized clinical trial. J Am Soc Nephrol. 2017;28:1259-1268.
229. Clarkson MJ, Bennett PN, Fraser SF, et al. Exercise interventions for improving objective physical function in patients with end-stage kidney disease on dialysis: a systematic review and meta-analysis. Am J Physiol Renal Physiol. 2019;316:F856-F872.
230. Pu J, Jiang Z, Wu W, et al. Efficacy and safety of intradialytic exercise in haemodialysis patients: a systematic review and meta-analysis. BMJ Open. 2019;9:e020633.
231. Watson EL, Gould DW, Wilkinson TJ, et al. Twelve-week combined resistance and aerobic training confers greater benefits than aerobic training alone in nondialysis CKD. Am J Physiol Renal Physiol. 2018;314: F1188-F1196.
232. Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int. 2017;92:313-323.
233. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-163.
234. Chang AR, Grams ME, Ballew SH, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301.
235. Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant. 2013;28(suppl 4):iv82-98.
236. Navaneethan SD, Yehnert H, Moustarah F, et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1565-1574.
237. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81:543-554.
238. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845-854.
239. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-39.
240. Cannon CP, Perkovic V, Agarwal R, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease according to baseline HbA1c, including those with HbA1c №7%: results from the CREDENCE Trial. Circulation. 2020;141:407-410.
241. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381: 1995-2008.
242. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
243. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306.
244. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357.
245. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373: 2117-2128.
246. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure [e-pub ahead of print]. N Engl J Med. https://doi.org/10.1056/NEJMoa2022190. Accessed September 2, 2020.
247. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487-493.
248. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63:221-228.
249. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69-79.
250. Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol. 2017;28:2263-2274.
251. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-88.
252. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154: 602-613.
253. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740-751.
254. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304-1311.
255. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98.
256. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004;27:1791-1793.
257. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.
258. Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312: 2668-2675.
259. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available at: www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed August 14, 2020.
260. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med. 2017;166:191-200.
261. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
262. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-549.
263. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11:338-342.
264. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491-497.
265. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16.
266. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29:759-764.
267. Ji L, Liu J, Yang J, et al. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: analysis of results from the CONSENT trial. Diabetes Obes Metab. 2018;20:1006-1013.
268. Stephen J, Anderson-Haag TL, Gustafson S, et al. Metformin use in kidney transplant recipients in the United States: an observational study. Am J Nephrol. 2014;40:546-553.
269. Vest LS, Koraishy FM, Zhang Z, et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data. Clin Transplant. 2018;32:e13302.
270. Alnasrallah B, Goh TL, Chan LW, et al. Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. BMC Nephrol. 2019;20:147.
271. Reinstatler L, Qi YP, Williamson RS, et al. Association of biochemical B(1)(2) deficiency with metformin therapy and vitamin B(1)(2) supplements: the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care. 2012;35:327-333.
272. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.
273. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691-704.
274. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-274.
275. Wanner C, Heerspink HJL, Zinman B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol. 2018;29:2755-2769.
276. Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119-129.
277. Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 trial. Am Heart J. 2018;200:83-89.
278. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249-259.
279. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials [e-pub ahead of print]. Lancet. https://doi.org/10.1016/S0140-6736(20)31824-9. Accessed September 2, 2020.
280. Solomon SD, Jhund P, Kosiborod MN, et al. Effect of dapagliflozin on renal function in heart failure with reduced ejection fraction: the DAPA-HF trial. Paper presented at: American Society of Nephrology Kidney Week. November 5-10, 2019;Washington DC.
281. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334.
282. Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8:27-35.
283. Williams SM, Ahmed SH. 1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice. Diabetes. 2019;68:1224-P.
284. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
285. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610-621.
286. Dekkers CCJ, Wheeler DC, Sjostrom CD, et al. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant. 2018;33:2005-2011.
287. Fioretto P, Del Prato S, Buse JB, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes Obes Metab. 2018;20:2532-2540.
288. Grunberger G. Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9:49-66.
289. Haneda M, Seino Y, Inagaki N, et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther. 2016;38:66-88.
290. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16:1102-1110.
291. Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015;17:152-160.
292. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962-971.
293. Pollock C, Stefansson B, Reyner D, et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:429-441.
294. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463-473.
295. Lo C, Toyama T, Wang Y, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018;9:CD011798.
296. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. J Clin Epidemiol. 2011;64:1283-1293.
297. Cai X, Shi L, Yang W, et al. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. J Med Econ. 2019;22:336-343.
298. Chin KL, Ofori-Asenso R, Si S, et al. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Sci Rep. 2019;9:3256.
299. Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020;35:274-282.
300. Wheeler DC, Stefansson BV, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics [e-pub ahead of print]. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa234. Accessed September 2, 2020.
301. Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J. 2018;11:749-761.
302. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11-23.
303. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72:3200-3223.
304. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41:255-323.
305. American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S135-S151.
306. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S111-S134.
307. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S98-S110.
308. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669-2701.
309. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 2015;6: 289-302.
310. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403-411.
311. Seidu S, Kunutsor SK, Cos X, et al. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes. 2018;12:265-283.
312. European Medicines Agency: Forxiga, INN-dapagliflozin. EPAR Product Information: Annex 1: Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf. Accessed August 14, 2020.
313. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-130.
314. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519-1529.
315. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375: 1834-1844.
316. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
317. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377: 1228-1239.
318. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373:2247-2257.
319. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605-617.
320. Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839-848.
321. Bethel MA, Mentz RJ, Merrill P, et al. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial. Diabetes Care. 2020;43: 446-452.
322. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131-138.
323. Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes - a post-hoc analysis of the ELIXA trial. Lancet Diabetes and Endocrinol. 2018;6:859-869.
324. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841-851.
325. Hanefeld M, Arteaga JM, Leiter LA, et al. Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Diabetes Obes Metab. 2017;19:1594-1601.
326. Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation. 2018;138:2908-2918.
327. Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-785.
328. Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19:336-347.
329. Dailey GE, Dex TA, Roberts M, et al. Efficacy and safety of lixisenatide as add-on in patients with T2D aged >=70 years uncontrolled on basal insulin in the getgoal-o study [abstract]. Endocrine Practice. 2018;24:48.
330. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39:222-230.
331. Idorn T, Knop FK, Jorgensen MB, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes Care. 2016;39:206-213.
332. Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther. 2017;8:101-114.
333. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515-527.
334. von Scholten BJ, Persson F, Rosenlund S, et al. The effect of liraglutide on renal function: a randomized clinical trial. Diabetes Obes Metab. 2017;19:239-247.
335. Vega-Hernandez G, Wojcik R, Schlueter M. Cost-effectiveness of liraglutide versus dapagliflozin for the treatment of patients with type 2 diabetes mellitus in the UK. Diabetes Ther. 2017;8:513-530.
336. Zueger PM, Schultz NM, Lee TA. Cost effectiveness of liraglutide in type II diabetes: a systematic review. Pharmacoeconomics. 2014;32:1079-1091.
337. American Diabetes Association. Standards of medical care in diabetes-2019 abridged for primary care providers. Clin Diabetes. 2019; 37:11-34.
338. Boye KS, Botros FT, Haupt A, et al. Glucagon-like peptide-1 receptor agonist use and renal impairment: a retrospective analysis of an electronic health records database in the U.S. population. Diabetes Ther. 2018;9:637-650.
339. Chatterjee S, Davies MJ, Heller S, et al. Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol. 2018;6:130-142.
340. Steinsbekk A, Rygg LO, Lisulo M, et al. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res. 2012;12:213.
341. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med. 2015;163:848-860.
342. Fogelfeld L, Hart P, Miernik J, et al. Combined diabetes-renal multifactorial intervention in patients with advanced diabetic nephropathy: proof-of-concept. J Diabetes Complications. 2017; 31:624-630.
343. Kopf S, Oikonomou D, von Eynatten M, et al. Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes. Acta Diabetol. 2014;51: 479-489.
344. Li T, Wu HM, Wang F, et al. Education programmes for people with diabetic kidney disease. Cochrane Database Syst Rev. 2011; 6:CD007374.
345. Steed L, Lankester J, Barnard M, et al. Evaluation of the UCL diabetes self-management programme (UCL-DSMP): a randomized controlled trial. J Health Psychol. 2005;10:261-276.
346. Zimbudzi E, Lo C, Misso ML, et al. Effectiveness of self-management support interventions for people with comorbid diabetes and chronic kidney disease: a systematic review and meta-analysis. Syst Rev. 2018;7:84.
347. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
348. Curtin RB, Walters BA, Schatell D, et al. Self-efficacy and self-management behaviors in patients with chronic kidney disease. Adv Chronic Kidney Dis. 2008;15:191-205.
349. Chen SH, Tsai YF, Sun CY, et al. The impact of self-management support on the progression of chronic kidney disease-a prospective randomized controlled trial. Nephrol Dial Transplant. 2011;26:3560-3566.
350. Teljeur C, Moran PS, Walshe S, et al. Economic evaluation of chronic disease self-management for people with diabetes: a systematic review. Diabet Med. 2017;34:1040-1049.
351. Boren SA, Fitzner KA, Panhalkar PS, et al. Costs and benefits associated with diabetes education: a review of the literature. Diabetes Educ. 2009;35:72-96.
352. UK Department of Health. Structured patient education in diabetes. Report from the Patient Education Working Group. London, UK, 2005.
353. National Institute for Health and Care Excellance. Diabetes in adults 2011. Available at: https://www.nice.org.uk/guidance/qs6 2011. Accessed August 14, 2020.
354. NDA. National Diabetes Audit 2016-17 - Report 1: Care Processes and Treatment Targets. NHS Digital, 2018. Available at: https://digital.nhs. uk/data-and-information/publications/statistical/national-diabetes-audit/ national-diabetes-audit-report-1-care-processes-and-treatment-targets-2 016-17. Accessed August 14, 2020.
355. NDA. National Diabetes Audit - Report 1 Care Processes and Treatment Targets 2017-18, Full Report. NHS Digital, 2019.
356. International Diabetes Federation. IDF Clinical practice recommendations for managing type 2 diabetes in primary care. Available at: https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html. Accessed August 14, 2020.
357. Chan JCN, Lim LL, Luk AOY, et al. From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions. Diabetes Care. 2019;42:2022-2031.
358. International Diabetes Federation. IDF Diabetes Altas 2019. Available at: https://diabetesatlas.org/en/resources/. Accessed August 14, 2020.
359. Kong AP, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry. Diabetes Care. 2014;37:1024-1031.
360. Miccoli R, Penno G, Del Prato S. Multidrug treatment of type 2 diabetes: a challenge for compliance. Diabetes Care. 2011;34(suppl 2):S231-S235.
361. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-1418.
362. Epping-Jordan JE, Pruitt SD, Bengoa R, et al. Improving the quality of health care for chronic conditions. Qual Saf Health Care. 2004;13:299-305.
363. Lim LL, Lau ESH, Kong APS, et al. Aspects of multicomponent integrated care promote sustained improvement in surrogate clinical outcomes: a systematic review and meta-analysis. Diabetes Care. 2018;41:1312-1320.
364. Seidu S, Achana FA, Gray LJ, et al. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. DiabetMed. 2016;33:280-289.
365. Leehey DJ, Collins E, Kramer HJ, et al. Structured exercise in obese diabetic patients with chronic kidney disease: a randomized controlled trial. Am J Nephrol. 2016;44:54-62.
366. Williams AF, Manias E, Walker RG. The devil is in the detail - a multifactorial intervention to reduce blood pressure in co-existing diabetes and chronic kidney disease: a single blind, randomized controlled trial. BMC Fam Pract. 2010;11:3.
367. Chan JC, So WY, Yeung CY, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care. 2009;32:977-982.
368. Funnell MM, Piatt GA. Diabetes quality improvement: beyond glucose control. Lancet. 2012;379:2218-2219.
369. McGill M, Blonde L, Chan JCN, et al. The interdisciplinary team in type 2 diabetes management: challenges and best practice solutions from real-world scenarios. J Clin Transl Endocrinol. 2017;7:21-27.
370. Patil SJ, Ruppar T, Koopman RJ, et al. Peer support interventions for adults with diabetes: a meta-analysis of hemoglobin A1c outcomes. Ann Fam Med. 2016;14:540-551.
371. Trump LJ, Mendenhall TJ. Community health workers in diabetes care: a systematic review of randomized controlled trials. Fam Syst Health. 2017;35:320-340.
372. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-841.
373. Wu HJ, Lau ESH, Ma RCW, et al. Secular trends in all-cause and cause-specific mortality in people with diabetes in Hong Kong, 2001-2016: a retrospective cohort study. Diabetologia. 2020;63:757-766.
374. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care. 2008;31: 1510-1515.
375. Ko GT, Yeung CY, Leung WY, et al. Cost implication of team-based structured versus usual care for type 2 diabetic patients with chronic renal disease. Hong Kong Med J. 2011;17(suppl 6):9-12.
376. Owolabi MO, Yaria JO, Daivadanam M, et al. Gaps in guidelines for the management of diabetes in low-and middle-income versus high-income countries - a systematic review. Diabetes Care. 2018;41:1097-1105.
377. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807-814.
378. Luk AO, Li X, Zhang Y, et al. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry. DiabetMed. 2016;33:1230-1239.
379. Bello AK, Ronksley PE, Tangri N, et al. Quality of chronic kidney disease management in Canadian primary care. JAMA Netw Open. 2019;2: e1910704.
380. Chan JC. What can we learn from the recent blood glucose lowering megatrials? J Diabetes Investig. 2011;2:1-5.
381. Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951-964.
382. Institute of Medicine (IOM) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman D, et al., eds. Clinical Practice Guidelines We Can Trust. Washington DC: IOM;2011.
383. Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Res Policy Syst. 2006;4:21.
384. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63:1308-1311.
385. Andad V, Kshirsagar AV, Navaneethan SD, et al. Direct renin inhibitors for preventing the progression of diabetic kidney disease (protocol). Cochrane Database Syst Rev. 2013;9:CD010724.
386. Natale P, Palmer SC, Ruospo M, et al. Potassium binders for chronic hyperkalemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6:CD013165.
387. McMahon EJ, Campbell KL, Bauer JD, et al. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2015;2:CD010070.
388. Palmer SC, Maggo JK, Campbell KL, et al. Dietary interventions for adults with chronic kidney disease. Cochrane Database Syst Rev. 2017;4: CD011998.
389. Lo C, Jun M, Badve SV, et al. Glucose-lowering agents for pre-existing and new onset diabetes in kidney transplant recipients. Cochrane Database Syst Rev. 2017;2:CD009966.
390. Li T, Wu HM, Wang F, et al. Education programs for people with diabetic kidney disease. Cochrane Database Syst Rev. 2011;6: CD007374.
391. Cochrane Handbook for Systematic Reviews of Interventions. Chichester UK: Wiley;2019.
392. Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380-382.
393. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011 ;343:d5928.
394. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.
395. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
396. Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol. 2013;66:140-150.

Другие статьи по теме

• Клинические Практические Рекомендации KDIGO 2012 по Диагностике и Лечению Хронической Болезни Почек
• Клинические практические рекомендации KDIGO 2018 по профилактике, диагностике, оценке и лечению гепатита С при хронической болезни почек
• Клинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней
• Клинические Практические Рекомендации KDIGO 2022 по тактике ведения диабета при хронической болезни почек